Influenza activity in the United States during the 2025-26 influenza season
Background Comprehensive influenza surveillance is conducted year-round in the United States to monitor changes in influenza activity. This report summarizes the 2025-26 U.S. influenza season. Methods Data from September 28, 2025 through October 3, 2026 were collected from national surveillance systems monitoring influenza through laboratory testing, outpatient and emergency department visits, hospitalizations, and mortality. Data modeled disease burden and assessed severity using established criteria. A subset of influenza positive specimens were genetically and antigenically characterized and assessed for antiviral susceptibility. Results Influenza activity peaked during the week ending December 27, 2025, five weeks earlier than the 2024-25 season. There were two waves of influenza activity with influenza A(H3N2) subclade K viruses predominating the season overall and during the first wave followed by a smaller B/Victoria wave. The majority of circulating A(H3N2) and B/Victoria viruses were antigenically drifted from 2025-26 influenza vaccine reference strains. Season severity was classified as moderate overall, with children (0-17 years old) experiencing a high severity season and adults experiencing a moderate severity season. Children experienced the highest percent of influenza-associated outpatient and emergency department visits compared to other age groups. This season's cumulative influenza-associated hospitalization rate in children is the highest hospitalization rate in the past 16 years. Additionally, there were 198 influenza-associated pediatric deaths reported to CDC as of October 29, 2026. Conclusions Although antigenically drifted A(H3N2) viruses predominated, the 2025-26 U.S. influenza season occurred within historic norms for timing and severity. Year-round surveillance remains critical for detecting changes in influenza viruses and monitoring influenza-associated morbidity and mortality.
Authors
- Shunte Moon (ORCID: https://orcid.org/0000-0002-7243-7901)
- Catherine H. Bozio (ORCID: https://orcid.org/0000-0001-6566-7138)
- Nguyen Ha Thao Vy
- Amanda C. Howa (ORCID: https://orcid.org/0000-0003-4160-5439)
- Sarabeth M. Mathis (ORCID: https://orcid.org/0000-0003-3131-307X)
- Daneisha Hawkins
- Arielle Colón (ORCID: https://orcid.org/0009-0001-3586-5392)
- Krista L. Kniss (ORCID: https://orcid.org/0000-0001-8464-4599)
- Stacy Huang
- Alicia Budd (ORCID: https://orcid.org/0000-0003-3936-164X)
- Angela Danielle Iuliano (ORCID: https://orcid.org/0000-0001-8742-3687)
- Larisa V. Gubareva (ORCID: https://orcid.org/0000-0002-3136-5550)
- Dawud Ujamaa
- Alissa C. O’Halloran (ORCID: https://orcid.org/0000-0002-7397-7870)
- Angiezel Merced-Morales
- Alexandra L. Busbee
- Rebecca J Garten Kondor (ORCID: https://orcid.org/0000-0002-2596-4282)
- Jenn Habeck
- Mira C. Patel (ORCID: https://orcid.org/0000-0002-6237-293X)
- Raheem Smith
- Katie Reinhart
- Xiao-yu Zheng
- Peter Daly
- Yingtao Zhou
- Nicholas Dempster
- Chao Zhang
Institutions
- Centers for Disease Control and Prevention (US)
- Centers for Disease Control and Prevention (UG)
- Centers for Disease Control and Prevention (KE)
Publication Details
- Journal
- medRxiv
- Published
- 2026-11-18
- DOI
- https://doi.org/10.64898/2026.11.16.26367927
- Primary Topic
- Influenza Virus Research Studies
- Type
- preprint
Funders
- Centers for Disease Control and Prevention
- National Center for Immunization and Respiratory Diseases